Merantix focuses on investing in pre-seed and seed-stage AI-native companies in Europe, particularly those developing B2B applications across diverse industries such as healthcare, manufacturing, finance, and logistics. Their strategy involves providing financial backing and integrating entrepreneurs into their AI ecosystem, offering access to talent, networks, and resources to accelerate growth.
33% of their portfolio is in Biotech & Life Sciences. Deal activity increased 50% year-over-year (3 deals in the last 12 months). Their most common stage is pre-seed (50% of deals). Average disclosed round size is $3.6M (across 6 rounds with reported amounts).
Portfolio
6
Fund Size
—
Top Stage
Pre Seed
Last 12 Mo
3
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Outpost Bio | Pre-Seed | $3.5M | Mar 2026 |
 FICUS Health | Seed | $3M | Dec 2025 |
| AArqh | Pre-Seed | $3.8M | Sep 2025 |
 Graph Therapeutics | Pre-Seed | $3M | Jan 2025 |
| BBriink | Seed | $3.9M | Sep 2024 |
 Vara | Series A | $4.4M | Oct 2022 |
Top Co-Investors
EquityPitcher Ventures1 shared
13Books1 shared
seed + speed Ventures1 shared
Founderful1 shared
Redstone1 shared
SquareOne1 shared
Atomico1 shared
OMERS Ventures1 shared
Vi Partners1 shared
Seedcamp1 shared
Last updated: 21 April 2026